HOW TO GET INVOLVED
PARTNER WITH US
It's never too early to get involved! Based on your objectives, we can create bespoke packages designed specifically for you.
From presenting your expertize on the main stage to hosting the infamous CAR-T Party. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
Discuss your objectives with Oleksiy Ihnatenko, Commercial Partnerships Manager; [email protected].
OR REGISTER YOUR INTEREST IN SPONSORSHIP FOR THE WORLD ONCOLOGY CELL THERAPY CONGRESS, HERE.
REGISTER AS A DELEGATE
Innovation in cell therapy for cancer is at an all-time high, with the exploration of autologous and allogeneic therapies derived from T cells, NK cells, macrophages and beyond.
Step into interactive discussions and engaging presentations on the hottest challenges facing the cell therapy industry today.
REGISTER YOUR INTEREST IN OUR SISTER EVENT, THE WORLD ONCOLOGY CELL THERAPY CONGRESS, HERE.
Previous Speakers
Dr Adil Duru
I received my Ph.D. from the Center for Infectious Medicine (CIM), Karolinska Institutet (KI), Sweden, in 2012 where I studied MHC-class I restricted-peptide based immunomodulation of T cells and NK cells. I moved for my post-doctoral studies at the Center for Hematology and Regenerative Medicine (HERM) at KI with a focus on developing novel cell culture agents and methods as well as genetic modification strategies for ex vivo NK cell expansion. In parallel, I investigated the impact of novel immunomodulatory drugs and biological agents on prognosis and treatment of multiple myeloma patients.
From 2015 until 2020, I continued my research as an Assistant Professor/Group Leader at the Nova Southeastern University (NSU) Cell Therapy Institute, FL, USA, in the field of tumor immunology and immunotherapy with a specific interest in investigating NK cell interactions with different primary solid tumour models such as Melanoma and Sarcoma and developing novel TCR- and CAR-based genetically modified NK cell immunotherapies. Furthermore, I established and directed the Cell Therapy Core Facility (CTC) at NSU, which is capable of design, development, pre-clinical evaluation and optimization of cell therapy products. Additionally, I am a cofounder and shareholder of the biotech company Vycellix, which is focused on developing innovative products enhancing the immune responses against cancer.
In 2020, I joined to Glycostem Therapeutics, Netherlands, as senior research manager where I am working to develop novel robust and efficient native and engineered NK cell-based immunotherapy regimens for high-risk cancers.
Alicia Bertolotti
Andrea Braun- Scherhag
Ann Ager
Anna Koptina
Bakul Gupta
Dr Bakul Gupta is the CEO and Co-founder of ImmTune Therapies, a preclinical stage cell therapy biotech which is developing safe, scalable and affordable in vivo cell therapies. The company is leveraging its unique platform to effectively deliver genetic cargoes directly to targeted cells, and applying it across different indications in cell and gene therapies.
Bakul founded the company in 2019, along with her business partner, Dr George Tetley after a 6-month long research into the challenges faced by current cell and gene therapy companies. She holds a PhD and BSc in Nanotechnology and Chemistry from the UNSW Australia, and finished her postdoctoral training with Prof. Molly Stevens at Imperial College London before starting ImmTune Therapies.
She has over 10 years of experience in designing nano- and bio-materials for a diverse set of biomedical applications and has previous experience in commercialisation of medical devices. She was recently listed as the Top 30 biotech entrepreneurs to watch as part of a report produced by BioBeat.
Behnam Sadeghi
Behnam Sadeghi graduated as medical doctor (MD) in 1995. Dr Sadeghi did his PhD in transplantation Immunology in 2009 at Karolinska Institute, Stockholm, Sweden. Since then, Dr Sadeghi’s research concentrated in the field of cell therapy and regenerative medicine both in clinical practice and experimental models. Dr Sadeghi established and applied decidua stromal cells (DSC) for the treatment of steroid refractory GVHD, ARDS and other acute inflammatory disorders in man. Other cell therapy modalities including bone marrow, adipose derived mesenchymal stromal cells (BM, Ad-MSC) are among his research interest. Currently, Dr Sadeghi is head of Translational Cell therapy Research group (TCR) at the department of CLINTEC, Karolinska Institute, Stockholm, Sweden.
Ben Taylor
Benjamin Rengstl
Dr. Benjamin Rengstl is a trained physician and biochemist. Since 2009, he is exploring the potential of the immune system to combat cancer and infectious diseases. Between 2014 and 2016, he received his approbation as well as a PhD and a MD degree from the University of Frankfurt, Germany. During his postdoctoral training, he developed chimeric antigen receptor (CAR)-engineered T-cell therapies against lymphomas and got trained in clinical pathology. In 2017, he joined BioNTech SE located in Mainz to develop a clinical CAR-T cell candidate for treatment of solid tumors. To improve CAR-T cell therapy, his team pioneered an in vivo expansion concept based on a liposomally formulated RNA vaccine for systemic delivery of CAR antigen (CAR T-cell Amplifying RNA Vaccine, CARVac). A FIH clinical trial assessing BioNTech´s novel CLDN6-specific CAR in combination with CARVac is currently ongoing. Furthermore, he is leading multiple programs to develop next generation cell- and RNA-based immunotherapies and further takes technology agnostic approaches to create new strategies for controlled modulation of the immune system.
Bernd Eschgfäller
Bryan Kobel
Carole Sansoz
Chris Baldwin
Dilip Patel
Dora Hammerl
Etienne Jousseaume
Hélène Negre
Hemant Dhamne
Ineke Jonker-Hoogerkamp
Inge Jedema
Inna Menkova
Jamal El-Mosleh
Jens Pahl, PhD
Joël Plumas
Juliana Dias Alves Pinto
Luca Gattinoni
Michael Hudecek
Michael Leek
Mikhail Steklov
Michael Traxlmayr
Olivier Negre
Paul Ibbett
Praveen Malhotra
Rebecca Street-Howard
Robert Igarashi
Rogier Rooswinkel
Sarah Tettamanti
Sebastian Torres
Stuart Curbishley
Sven Kili
Sicco Popma
Troels Jordansen
Tomasz Rygiel
OUR CELL THERAPY COMMUNITY
Register your interest
The agenda for the World Oncology Cell Therapy Congress Europe will be released soon.
Fill out this form to register your interest and be the first to recieve the agenda when it becomes available!
REGISTER YOUR INTEREST
Why Attend
Europe is a powerhouse of research but has been struggling to keep pace with development in the US. Get multiple perspectives during panel discussions on how to attract investment from C-suite executives and investors and explore European regulatory and reimbursement challenges for the cell therapy field. At the Onco Cell Therapy Summit: Europe 2022, we:
- Brought together over 200 of Europe’s leading innovators and investors to drive partnerships, collaborations and drive adoptive cell therapies to the market
- Addressed durability, reduce exhaustion, and build in optimal approaches for targeting antigen heterogeneity to hit the tumour microenvironment
- Explored genome-editing, iPSC-derived approaches and management strategies for chromosomal abnormalities and translocations for allogeneic cell therapy development
- Established robust, scalable and flexible vein-to-vein processes to enhance just in time delivery of cell therapies
TESTIMONIALS
2023 PARTNERS
Gold Sponsor
Exhibitors
Miltenyi Biotec
Website: https://www.miltenyibiotec.com/GB-en/
Please visit our website for more information.PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you – from presenting your expertise on the main stage, to hosting a private dinner. You can partner with us showcase your brand and make valuable new connections. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding & Networking.
To discuss your objectives and partnership opportunities please contact Oleksiy Ihnatenko, Commercial Partnerships Manager, [email protected]
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact Laura Hobson, Senior Marketing Manager, [email protected]
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
TERMS & CONDITIONS
In the event that Kisaco Research postpones an event for any reason or changes the event format to ‘virtual event’, any in-person registrations for this event will be automatically transferred to the virtual registration package. The delegate will receive a credit note for the difference in ticket value from the fee paid. You may use this credit for another Kisaco Research event to be mutually agreed with Kisaco Research, which must occur within 12 months from the date of the event which the delegate had originally registered for.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.